Novavax (NVAX) Scheduled to Post Quarterly Earnings on Tuesday

Novavax (NASDAQ:NVAX) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.87) per share for the quarter. Novavax has set its FY 2024 guidance at EPS.

Novavax (NASDAQ:NVAX) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.82 by ($0.83). The company had revenue of $415.50 million during the quarter, compared to the consensus estimate of $458.57 million. During the same quarter in the prior year, the company posted $0.58 earnings per share. The business’s revenue for the quarter was down 2.1% compared to the same quarter last year. On average, analysts expect Novavax to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Novavax Stock Up 3.1 %

NASDAQ:NVAX traded up $0.28 during mid-day trading on Tuesday, hitting $9.40. 2,109,565 shares of the company traded hands, compared to its average volume of 9,853,909. The stock’s fifty day moving average price is $11.87 and its 200-day moving average price is $12.24. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -3.30 and a beta of 2.10. Novavax has a one year low of $3.53 and a one year high of $23.86.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on NVAX. B. Riley reiterated a “buy” rating and set a $26.00 price objective (up from $23.00) on shares of Novavax in a research note on Thursday, October 10th. JPMorgan Chase & Co. upped their price target on shares of Novavax from $8.00 to $9.00 and gave the stock an “underweight” rating in a research report on Monday, August 12th. Finally, Jefferies Financial Group decreased their price objective on shares of Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Novavax currently has an average rating of “Hold” and an average price target of $17.83.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.